Nrx receives nasdaq notice of listing compliance

Radnor, pa. , dec. 2, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced it received written notice on december 1, 2022 from the nasdaq stock market informing nrx pharmaceuticals that it has regained compliance with the minimum bid price requirement under the nasdaq listing rule 5450(a)(1) (which requires the company to maintain a minimum closing bid price of $1.00 per share) and the matter is now closed.
NRXP Ratings Summary
NRXP Quant Ranking